openPR Logo
Press release

Critics Applaud John E. Jacob's Book "I Will F.E.A.R. No Evil"

06-13-2025 11:20 PM CET | Associations & Organizations

Press release from: ABNewswire

Critics Applaud John E. Jacob's Book "I Will F.E.A.R. No Evil"

John E. Jacob, former President and CEO of the National Urban League, and a lifelong advocate for racial equality and leadership, has received significant acclaim for his debut book, I Will F.E.A.R. No Evil. The memoir, which draws from Jacob's personal experiences and decades of leadership, has been praised for its powerful insights into the Black American experience, the challenges of racial segregation, and the importance of activism and community empowerment.

Marc H. Morial, President and CEO of the National Urban League, expressed his admiration for the book, stating:

" Jacob's memoir is a powerful antidote to those who would diminish the prospects of Black Americans. His time spent growing up in deep poverty in the racially segregated Houston, Texas, of mid-20th century America is a testament to the intelligence and determination that has fueled millions of Black Americans. His decades of leadership in the National Urban League, culminating in his role as President and CEO during the Reagan and Bush administrations, speak to his unwavering commitment to challenge conservative policies and advocate for the strengthening of Black communities ."

Morial continued, " As we face the challenges ahead, Jacob's record of advocacy offers an example of leadership we would all do well to consider ."

Bill Johnson, former CEO of the Urban League of Rochester (1972-1993) and former Mayor of Rochester, NY (1994-2005), also weighed in on the book, sharing:

"I had the opportunity to work with John Jacob as an affiliate director and later as the CEO of the National Urban League. As a young leader, I benefited from his willingness to share his knowledge and experience. As a colleague, I valued his stewardship of the League during a time when hard-fought gains were under attack. He never wavered in the face of adversity, and he skillfully mobilized allies to keep the focus on the nation's responsibility to ensure equity and inclusion for all. His book should be essential reading for anyone who seeks a better understanding of America's struggle to achieve these goals ."

When asked about the overwhelmingly positive response to his book, Jacob commented:

" I wrote this memoir to warn American society that its refusal to provide millions of Americans with the education and job training necessary to prepare them for the 21st century would have disastrous social and economic consequences. I'm happy to see that people relate to my work and support my stance."

Now more than ever, Jacob's memoir offers a fresh, penetrating assessment of a period often inaccurately described as one of conservative hegemony. I Will F.E.A.R. No Evil is now available for purchase on Amazon [https://www.amazon.com/I-WILL-FEAR-NO-EVIL/dp/B0F1M7CRP2/ref=sr_1_4?dib=eyJ2IjoiMSJ9.X5KojmWViaIgH0i11Z4H0jfsQWP_x30_re9Bsw33nEZesS22Ivr5naN9lDoF_YMC0eYTikh_T3N5qIoK4TTo78eIdEaDO3EllNyXVhjVadXc9GC7xkPs_QGga9konQUsXtATFm_PzgftmFWbV87AGCwRoaIm_74DE-cknjjhtgKjSaWtGJVLCWP9CZoq-7p8SRlYDGwI2lPZ3w5M6o0XPXUjhO3PI-k7bYRRJBxHjJ8.Nvlz7tRDkUs5krLnD-j8fs4gXXATppVOcPRiBQNBsFc&dib_tag=se&qid=1746002113&refinements=p_27%3AJOHN+E.+JACOB&s=books&sr=1-4&text=JOHN+E.+JACOB].

John E. Jacob had distinguished careers as a corporate executive and U.S. civil rights leader. He was Executive VP and Chief Communications Officer at Anheuser-Busch (1994-2008), serving on its Board and key committees. Reporting to Chairman August Busch III, he played a vital role in U.S. and international business. Jacob also served on 16+ corporate and charitable boards, including Morgan Stanley, Coca-Cola Enterprises, and The Drucker Foundation. He retired from Anheuser-Busch in 2008.

Facebook: https://www.facebook.com/profile.php?id=61571669693427

Instagram: https://www.instagram.com/author.johnejackob/

Twitter X: https://x.com/jackob57170

TikTok: https://www.tiktok.com/@johnejackob

Media Contact
Company Name: John E. Jacob
Contact Person: John E. Jacob
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=critics-applaud-john-e-jacobs-book-i-will-fear-no-evil]
Phone: 305-206-0054
Address:20155 NE 38th Court
City: Aventura
State: Florida
Country: United States
Website: https://johnejakejacob.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Critics Applaud John E. Jacob's Book "I Will F.E.A.R. No Evil" here

News-ID: 4066829 • Views:

More Releases from ABNewswire

Polycythemia Vera Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therapeu
Polycythemia Vera Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Polycythemia Vera pipeline constitutes 8+ key companies continuously working towards developing 10+ Polycythemia Vera treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Polycythemia Vera Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsigh …
The Key Myelofibrosis Companies in the market include - Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others. DelveInsight's "Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myelofibrosis, historical and forecasted epidemiology as well as the Myelofibrosis market trends in the United States, EU4 (Germany, Spain,
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentec
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Obser …
The Key Asthma Companies in the market inlcude - GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others. DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Asthma, historical and
Inflammatory Bowel Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly and Company, Gilead
Inflammatory Bowel Disease Market Positioned for Accelerated Development Through …
The Key Inflammatory Bowel Disease Companies: AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others DelveInsight's "Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding

All 5 Releases


More Releases for Jacob

Master Electrician Jacob Lehmann Expands Service Area
Local electrical business now serving wider Milwaukee region WAUWATOSA, WI - Jacob Lehmann has expanded his electrical contracting business to serve more communities across southeastern Wisconsin. His company, Lehmann Electrical & Design, now covers homes and businesses throughout Milwaukee County, Wauwatosa, Brookfield and neighboring areas. Lehmann launched his company in 2020 after getting his Master Electrician license at age 26. What started as just him working alone has grown into a team
Former Bankers Launch Christian Lifestyle Brand, Jacob Rachel
Two ex-finance professionals and a real estate manager create Jacob Rachel to offer Christian gifts and jewelry inspired by their faith. Image: https://www.globalnewslines.com/uploads/2025/03/b10c057b352e3c74f830ac3539ba0019.jpg SINGAPORE - 7 MARCH, 2025 - Former bankers Rachel Ang and Adelyn Yew, along with real estate manager Edwin Teo, launched Jacob Rachel, a rapidly growing Christian lifestyle brand, in Singapore in 2018. It offers a collection of Christian gifts and jewelry for men and women designed to help
The Young Businessman Jacob Handley Announces the Launch of FilingWiz
Newest Player in the Industry that Simplifies the Process of Filing Business in the USA Colorado, USA, July 8, 2021 – The 21-year old businessman, Jacob Handley has founded FilingWiz which aims to help businesses in the initial phase of registering an L.L.C. or corporation, creating a website, and digital marketing. FilingWiz offers those who want to establish their businesses in the country with seamless and fast processing while being compliant
iPOP ALUMN JACOB BATALON GETS HIS FIRST MAJOR ROLE
(Los Angeles, August 29, 2016) Jacob Batalon, an actor new to the industry, has just landed a major role in the new upcoming blockbuster film, Spiderman: Homecoming. It is scheduled for release in summer 2017. Jacob will play Ned Leeds, Peter Parker’s best friend. Jacob is a relative unknown. He was discovered and signed with his agent at the iPOP! talent convention last year. iPOP! is the world’s leading talent
Jacob Fleming’s MENA Renewable Energy Forum 26th -28th October 2009
The oil producing countries of Middle East and North Africa have been leading the Non-renewable energy race for the past few decades. However, with the world’s oil reserves predicted to run out within a few years’ time, these countries are turning their sights to leading a new race – A race to become the world’s leading exporters of renewable energy. The MENA region has vast quantities of natural resources which
Jacob Fleming’s Contemporary Internal Audit Conference 2009
With the slowing economy it is imperative to sharpen risk assessment practices to focus on the ever expanding range of strategic, operational and business risks. With expanding financial and market risk, internal audit is subjected to enhanced expectations from audit committees and face growing pressure to reduce audit cycle times and costly audit processes. The increasing rate of merger and acquisitions in current state of economy coupled with the recent